We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after October 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
PLURIPOTENT STEM CELL-DERIVED BROWN ADIPOCYTES, PLURIPOTENT STEM CELL-DERIVED CELL AGGREGATE, METHOD FOR PRODUCING SAME, AND CELL THERAPY AND MEDICAL THERAPY THEREFOR
METHOD FOR ASSESSING MYELODYSPLASTIC SYNDROME OR MYELOID TUMOR PREDISPOSITION, POLYPEPTIDE AND ANTIBODY THEREFOR, AND CANDIDATE SCREENING METHOD FOR THERAPEUTIC DRUG OR PROPHYLACTIC DRUG THEREFOR
HIGHLY FUNCTIONAL LIVER CELLS DERIVED FROM PLURIPOTENT STEM CELLS, METHOD FOR PRODUCING SAME, AND METHOD FOR TESTING METABOLISM/TOXICITY OF DRUG
METHOD FOR THE CREATION OF A DATABASE FOR INITIAL ASSESSMENT OF THE EFFECTIVENESS OF ACTIVE AGENTS IN TUMOUR THERAPY